Judy F. Gordon
Geen lopende functies
Profiel
Judy F.
Gordon is the founder of ClinReg Consulting Services, Inc. She previously worked as Head-Regulatory Affairs at Iconic Therapeutics, Senior Vice President-Regulatory Affairs at Glaukos Corp., and Senior Vice President-Research & Development at Chiron Vision Corp.
She holds a doctorate degree from Alma Mater Studiorum - Università di Bologna and an undergraduate degree from the University of California Los Angeles Graduate School.
Eerdere bekende functies van Judy F. Gordon
Bedrijven | Functie | Einde |
---|---|---|
GLAUKOS CORPORATION | General Counsel | - |
Chiron Vision Corp. | Chief Tech/Sci/R&D Officer | - |
ClinReg Consulting Services, Inc. | Founder | - |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | General Counsel | - |
Opleiding van Judy F. Gordon
Alma Mater Studiorum - Università di Bologna | Doctorate Degree |
University of California Los Angeles Graduate School | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
GLAUKOS CORPORATION | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Chiron Vision Corp. | |
ClinReg Consulting Services, Inc. |